Assessment of imatinib mesylate adherence of patients with chronic myeloid leukemia
Keywords:
Leucemia Mielóide Crônica, Mesilato de Imatinibe, Educação em Saúde, Adesão ao tratamento farmacológicoAbstract
Chronic Mielogenous Leukemia (CML) is a clonal hematologic disease that can be controlled with oral pharmacotherapy. One of the most important factors that influences the treatment is the patient adherence to the prescribed medication. The goal of this study was to compare the adherence of patients with CML treated with imatinib mesylate before and after the pharmaceutical intervention.
The first phase of the study consisted on the application of two questionnaires: Morisky’s et al. (evaluate the adherence to treatment) and Svarstad’s et al. (evaluate patient behavior regarding adherence; the belief in the treatment and identify the presence of barriers to follow therapy). On the second phase each patient received a pharmaceutical intervention. Approximately three months later the two questionnaires were reapplied. The data obtained was analyzed by simple descriptive analysis and Wilcoxon’s test.
In all 30 patients of an oncologic hospital were recruited and 24 completed the study. Before the intervention 15 participants had intermediate or low adherence according to Morisky et al. questionnaire; after intervention five had intermediate adherence and 19 high (p=0,005). According to Svarstad et al. questionnaire, before the intervention eight patients had potential non-compliance, 17 participants presented barriers to belief in the treatment and eigth presented barriers to follow therapy. After intervention, the results were, respectively: 11 (p = 0.497), 11 (p = 0.035) and two (p = 0.034).
With simple and low cost measures, like the pharmaceutical intervention, it is possible to improve the patient adherence to the oral treatment of CML.
Downloads
Downloads
Published
How to Cite
Issue
Section
License
The authors hereby transfer, assign, or otherwise convey to RBFHSS: (1) the right to grant permission to republish or reprint the stated material, in whole or in part, without a fee; (2) the right to print republish copies for free distribution or sale; and (3) the right to republish the stated material in any format (electronic or printed). In addition, the undersigned affirms that the article described above has not previously been published, in whole or part, is not subject to copyright or other rights except by the author(s), and has not been submitted for publication elsewhere, except as communicated in writing to RHFHSS with this document.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC-BY-NC-ND) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Serlf-archiving policy
This journal permits and encourages authors to post and archive the final pdf of the articles submitted to the journal on personal websites or institutional repositories after publication, while providing bibliographic details that credit its publication in this journal.
